Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)

Cardiovascular Research

Volumn 103, Issue 3, 2014, Pages 395-404

  Potì, Francesco ^a   Simoni, Manuela ^a   Nofer, Jerzy Roch ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Atherosclerosis; High density lipoproteins; Inflammation; Sphingosine 1 phosphate

Indexed keywords

HIGH DENSITY LIPOPROTEIN; SPHINGOSINE 1 PHOSPHATE; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL MODEL; ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; PROTECTION; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; PROTECTIVE FACTORS; RISK FACTORS; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84905560895     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu136     Document Type: Review

References (114)

1. Gordon T, CastelliWP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714
2. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
3. CastelliWP, Garrison RJ, WilsonPW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838
4. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19(Suppl A):A2-A11
5. Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA. High-density lipoprotein and atherosclerosis regression evidence from preclinical and clinical studies. Circ Res 2014;114: 205-213
6. Nofer J-R. Hyperlipidaemia and cardiovascular disease: The quantity does not turn into quality! Curr Opin Lipidol 2013;24:366-368
7. Rosenson RS, Brewer HB, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR,Webb NR. Translation of high-density lipoprotein function into clinical practice: Current prospects and future challenges. Circulation 2013;128:1256-1267
8. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, TeoK,WeintraubW. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267
9. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291
10. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122
11. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS, dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome.NEngl J Med 2012;367:2089-2099
12. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, De Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, De Bakker PI, Klungel OH, Maitland-Van Der Zee AH, Peters BJ, De Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van Der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Kö nig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van deWerf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, ODonnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 2012;380:572-580
13. Rye K-A, Barter PJ. Regulation of high-density lipoprotein metabolism. Circ Res 2014; 114:143-156
14. Huang R, Silva RAGD, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011;18:416-422
15. Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013;54:2575-2585
16. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-433
17. Sachinidis A, Kettenhofen R, Seewald S, Gouni-Berthold I, Schmitz U, Seul C, Ko Y, Vetter H. Evidence that lipoproteins are carriers of bioactive factors. Arterioscler Thromb Vasc Biol 1999;19:2412-2421
18. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001;276:31780-31785
19. Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S-I, Noda K, Okajima F, Saku K. Correlation of high density lipoprotein (HDL)-Associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005;178: 199-205
20. Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 2014; doi:10.1194/jlr.R046300
21. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012;22:50-60
22. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012;30:69-94
23. Carr JM, Mahalingam S, Bonder CS, Pitson SM. Sphingosine kinase 1 in viral infections. Rev Med Virol 2013;23:73-84
24. Finney CA, Hawkes CA, Kain DC, Dhabangi A, Musoke C, Cserti-Gazdewich C, Oravecz T, Liles WC, Kain KC. S1P is associated with protection in human and experimental cerebral malaria. Mol Med 2011;17:717-725
25. Pyne NJ, Tonelli F, Lim KG, Long JS, Edwards J, Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012;40:94-100
26. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1- phosphate. Trends Endocrinol Metab 2007;18:300-307
27. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011;11:403-415
28. Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. Cell Metab 2012; 16:420-434
29. Takabe K, Paugh SW, Milstien S, Spiegel S. Inside-out signaling of sphingosine-1- phosphate: Therapeutic targets. Pharmacol Rev 2008;60:181-195
30. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000; 352(Pt 3):809-815
31. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005; 309:1735-1739
32. Schwab SR, Cyster JG. Finding away out: Lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-1301
33. Guo S, Yu Y, Zhang N, Cui Y, Zhai L, Li H, Zhang Y, Li F, Kan Y, Qin S. Higher level of plasma bioactive molecule sphingosine 1-phosphate inwomenis associated with estrogen. Biochim Biophys Acta 2014;1841:836-846
34. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng Y-W, Huang Y, Cyster JG, Coughlin SR. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-298
35. Yatomi Y. Sphingosine 1-phosphate in vascular biology: Possible therapeutic strategies to control vascular diseases. Curr Pharm Des 2006;12:575-587
36. OhkawaR,Nakamura K,OkuboS, Hosogaya S, OzakiY, Tozuka M, Osima N, Yokota H, Ikeda H, Yatomi Y. Plasma sphingosine-1-phosphate measurement in healthy subjects: Close correlation with red blood cell parameters. Ann Clin Biochem 2008;45:356-363
37. Hänel P, Andréani P, Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21:1202-1209
38. Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, Gräler MH. Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J Immunol 2010;184:4133-4142
39. Venkataraman K, Lee Y-M, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008;102:669-676
40. Sato K, Okajima F. Role of sphingosine 1-phosphate in anti-Atherogenic actions of highdensity lipoprotein.World J Biol Chem 2010;1:327-337
41. Kimura T, Tomura H, Mogi C, Kuwabara A, Ishiwara M, Shibasawa K, Sato K, Ohwada S, Im D-S, Kurose H, Ishizuka T, Murakami M, Okajima F. Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal 2006;18:841-850
42. Wilkerson BA, Grass GD, Wing SB, Argraves WS, Argraves KM. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: High density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J Biol Chem 2012; 287:44645-44653
43. Bode C, Sensken SC, Peest U, Beutel G, Thol F, Levkau B, Li Z, Bittman R, Huang T, Tö lle M, van Der Giet M, Gräler MH. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem 2010;109:1232-1243
44. Nishi T, Kobayashi N, Hisano Y, KawaharaA, Yamaguchi A. Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta 2013;1841: 759-765
45. Mendoza A, Bréart B, Ramos-Perez WD, Pitt LA, Gobert M, Sunkara M, Lafaille JJ, Morris AJ, Schwab SR. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep 2012;2:1104-1110
46. Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, Hait NC, Maceyka M, Milstien S, Takabe K, Spiegel S. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J 2013;27: 1001-1011
47. Hisano Y, Kobayashi N, Yamaguchi A, Nishi T. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS ONE 2012;7: E38941
48. Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 2011;122:1416-1426
49. Kobayashi N, Nishi T, Hirata T, Kihara A, Sano T, Igarashi Y, Yamaguchi A. Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J Lipid Res 2006;47:614-621
50. Kobayashi N, Kobayashi N, Yamaguchi A, Nishi T. Characterization of the ATPdependent sphingosine 1-phosphate transporter in rat erythrocytes. J Biol Chem 2009;284:21192-21200
51. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103: 16394-16399
52. Ito S, Iwaki S, Koike K, Yuda Y, Nagasaki A, Ohkawa R, Yatomi Y, Furumoto T, Tsutsui H, Sobel BE, Fujii S. Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes. Coron Artery Dis 2013;24:642-650
53. Cartwright TA, Campos CR, Cannon RE, Miller DS. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J Cereb Blood Flow Metab 2013;33:381-388
54. Japtok L, Schaper K, Bäumer W, Radeke HH, Jeong SK, Kleuser B. Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype. PLoS ONE 2012;7:e49427
55. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, Nagahashi M, Harikumar KB, Hait NC, Milstien S, Spiegel S. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem 2010;285:10477-10486
56. Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, Tosaka M, Yoshimoto Y, KuwabaraA,Okajima F. Critical role ofABCA1transporter in sphingosine 1-phosphate release from astrocytes. J Neurochem 2007;103:2610-2619
57. Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, Tosaka M, Yoshimoto Y, Kuwabara A, Okajima F. HDL-like lipoproteins in cerebrospinal fluid affect neural cell activity through lipoprotein-Associated sphingosine 1-phosphate. Biochem Biophys Res Commun 2007;359:649-654
58. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlbäck B. Endothelium-protective sphingosine-1-phosphate provided by HDL-Associated apolipoprotein M. Proc Natl Acad Sci USA 2011;108:9613-9618
59. Davidson WS, Silva RAGD, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009;29:870-876
60. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlbäck B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006;47:1833-1843
61. Sevvana M, Ahnström J, Egerer-Sieber C, Lange HA, Dahlbäck B, Muller YA. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009;393:920-936
62. Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM, von Eckardstein A. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011;219: 855-863
63. Christoffersen C, Nielsen LB. Apolipoprotein M: Bridging HDL and endothelial function. Curr Opin Lipidol 2013;24:295-300
64. Elsøe S, Ahnström J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, Binder CJ, Björkbacka H, Dahlbäck B, Nielsen LB. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012;221: 91-97
65. Ahnström J, Faber K, Axler O, Dahlbäck B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007;48:1754-1762
66. Liu M, Seo J, Allegood J, Bi X, Zhu X, Boudyguina E, Gebre AK, Avni D, Shah D, Sorci-ThomasMG, Thomas MJ, Shelness GS, Spiegel S, Parks JS. Hepatic apolipoprotein M (ApoM) overexpression stimulates formation of larger ApoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J Biol Chem 2014;289: 2801-2814
67. Deutschman DH, Carstens JS, Klepper RL, Smith WS, PageMT, Young TR, Gleason LA, Nakajima N, Sabbadini RA. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003;146:62-68
68. Sattler KJE, Elbasan S, Keul P, Elter-Schulz M, Bode C, Gräler MH, Bröcker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010;105:821-832
69. Argraves K, Sethi A, Gazzolo P, Wilkerson B, Remaley A, Tybjaerg-Hansen A, Nordestgaard B, Yeatts S, Nicholas K, Barth J, Argraves W. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011;10:70
70. Knapp M, Baranowski M, Czarnowski D, Lisowska A, Zabielski P, Górski J, Musiał W. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit 2009;15:CR490-CR493
71. Knapp M, Lisowska A, Zabielski P, Musiał W, Baranowski M. Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. Prostaglandins Other Lipid Mediat 2013;106:53-61
72. Egom EE, Mamas MA, Chacko S, Stringer SE, Charlton-Menys V, El-Omar M, Chirico D, Clarke B, Neyses L, Cruickshank JK, Lei M, Fath-Ordoubadi F. Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol 2013;4:130
73. Kowalski GM, Carey AL, Selathurai A, Kingwell BA, Bruce CR. Plasma sphingosine-1- phosphate is elevated in obesity. PloS ONE 2013;8:e72449
74. Tong X, Peng H, Liu D, Ji L, Niu C, Ren J, Pan B, Hu J, Zheng L, Huang Y. High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: Relationship with HDL-Associated sphingosine-1-phosphate. Cardiovasc Diabetol 2013;12:27
75. Mineo C, Shaul PW. Function of scavenger receptor class B type I in atherosclerosis. Curr Opin Lipidol 2012;23:487-493
76. Nofer J-R, van Der Giet M, Tö lle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Gödecke A, Ishii I, Kleuser B, Schäfers M, Fobker M, ZidekW, Assmann G, ChunJ, Levkau B.HDLinduces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-581
77. Tö lle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van Der Giet M, Nofer J-R. HDL-Associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008;28:1542-1548
78. Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, Sekiguchi A, Ishiwara M, Im D-S, Sato K, Murakami M, Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006;281: 37457-37467
79. Kimura T, Mogi C, Tomura H, Kuwabara A, Im D-S, Sato K, Kurose H, Murakami M, Okajima F. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol 2008;181:7332-7340
80. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, Murakami M, Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003;23:1283-1288
81. Miura S, Fujino M, Matsuo Y, Kawamura A, Tanigawa H, Nishikawa H, Saku K. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003;23: 802-808
82. Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, Hammad SM, Argraves WS. High density lipoprotein-Associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem 2008;283: 25074-25081
83. Damirin A, Tomura H, Komachi M, Liu J-P, Mogi C, Tobo M, Wang J-Q, Kimura T, Kuwabara A, Yamazaki Y, Ohta H, Im D-S, Sato K, Okajima F. Role of lipoprotein-Associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 2007;292:H2513-H2522
84. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, Raffai R. Highdensity lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-Associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 2010;298:H1022-H1028
85. Kimura T, Tomura H, Sato K, Ito M, Matsuoka I, Im DS, Kuwabara A, Mogi C, Itoh H, Kurose H, Murakami M, Okajima F. Mechanism and role of high density lipoprotein-induced activation of AMP-Activated protein kinase in endothelial cells. J Biol Chem 2010;285:4387-4397
86. Matsuo Y, Miura S, Kawamura A, Uehara Y, Rye K-A, Saku K. Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis 2007;194:159-168
87. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-Associated lysosphingolipids. J Biol Chem 2001;276:34480-34485
88. Krishna SM, Seto SW, Moxon JV, Rush C,Walker PJ, Norman PE, Golledge J. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol 2012; 181:706-718
89. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 2007;150:470-479
90. Norata GD,MarchesiP, Pirillo A, Uboldi P,Chiesa G, MainaV, Garlanda C,Mantovani A, Catapano AL. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008;28: 925-931
91. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 2005;111:2805-2811
92. Tatematsu S, Francis SA, Natarajan P, Rader DJ, Saghatelian A, Brown JD, Michel T, Plutzky J. Endothelial lipase is a critical determinant of high-density lipoproteinstimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler Thromb Vasc Biol 2013;33:1788-1794
93. Tamama K, Tomura H, Sato K, Malchinkhuu E, Damirin A, Kimura T, Kuwabara A, Murakami M, Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 2005;178:19-23
94. Chrisman TD, Perkins DT, Garbers DL. Identification of a potent serum factor that causes desensitization of the receptor for C-Type natriuretic peptide. Cell Commun Signal 2003;1:4
95. González-Díez M, Rodríguez C, Badimon L, Martínez-González J. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin. Thromb Haemost 2008;100: 119-126
96. Frias MA, JamesRW, Gerber-Wicht C, Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate. Cardiovasc Res 2009;82:313-323
97. Frias MA, Lang U, Gerber-Wicht C, James RW. Native and reconstituted HDL protect cardiomyocytes fromdoxorubicin-induced apoptosis. Cardiovasc Res 2010;85:118-126
98. Morel S, Frias MA, Rosker C, JamesRW, Rohr S, Kwak BR. The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovasc Res 2012;93: 41-49
99. Weigert A, Weis N, Brüne B. Regulation of macrophage function by sphingosine-1- phosphate. Immunobiology 2009;214:748-760
100. Dueñas AI, Aceves M, Fernández-Pisonero I, Gómez C, Orduña A, Crespo MS, García-Rodríguez C. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate. Cardiovasc Res 2008; 79:537-544
101. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B. Highdensity lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006;114:1403-1409
102. Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Gräler M, Heusch G, Levkau B. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011;108:314-323
103. Skoura A, Michaud J, Im D-S, Thangada S, Xiong Y, Smith JD, Hla T. Sphingosine-1- phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:81-85
104. Shimizu T, Nakazawa T, Cho A, Dastvan F, Shilling D, Daum G, Reidy MA. Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteries. Circ Res 2007;101:995-1000
105. Grabski AD, Shimizu T, Deou J, MahoneyWMJr, Reidy MA, Daum G. Sphingosine-1- phosphate receptor-2 regulates expression of smooth muscle alpha-Actin after arterial injury. Arterioscler Thromb Vasc Biol 2009;29:1644-1650
106. Bot M, Van Veldhoven PP, De Jager SCA, Johnson J, Nijstad N, Van Santbrink PJ, Westra MM, Van Der Hoeven G, Gijbels MJ, Müller-Tidow C, Varga G, Tietge UJF, Kuiper J, Van Berkel TJC, Nofer J-R, Bot I, Biessen EAL. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. PLoS ONE 2013;8:e63360
107. Poti F, Bot M, Costa S, Bergonzini V, Maines L, Varga G, Freise H, Robenek H, Simoni M, Nofer J-R. Sphingosine kinase inhibition exerts both pro- and anti-Atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(2/2)) mice. Thromb Haemost 2012;107:552-561
108. Nofer J-R, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EAL. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501-508
109. Keul P, Tö lle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M, van Der Giet M, Levkau B. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007;27: 607-613
110. Klingenberg R, Nofer J-R, Rudling M, Bea F, Blessing E, Preusch M, Grone HJ, Katus HA, Hansson GK, Dengler TJ. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:2392-2399
111. Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E,Weber C, Simoni M, Nofer J-R. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R2/2) mice. Vascul Pharmacol 2012;57:56-64
112. Wang G, Kim RY, Imhof I, Honbo N, Luk FS, Li K, Kumar N, Zhu BQ, EberléD, Ching D, Karliner JS, Raffai RL. The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol 2014;63:132-143
113. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106:951-961
114. PotìF, Gualtieri F, Sacchi S, Weißen-Plenz G, Varga G, Brodde M, Weber C, Simoni M, Nofer J-R. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R2/2 mice. Arterioscler Thromb Vasc Biol 2013; 33:1505-1512.